Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue: +27.0%
EPS: −40.3%
Free cash flow: −140.2%
Total debt: +4.46%

Quarter to September 2026, against a year earlier

Insider buying

24.81 1.22 −4.69%

Follow CAI

Alert me

Market cap: $7.4B
P/E: 77.7×
Fwd P/E: 254×
Dividend yield: —
F-score: n/a
Altman Z: 3.55
Beneish M: −2.71
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Caris Life Sciences,�Inc. (CAI) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023
Cost of services - Molecular profiling services	767 94.42%	349 84.68%	279 91.06%
Cost of services - Pharma research and development services	45 5.58%	63 15.32%	27 8.94%
Revenue	812	412	306

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023
Cost of services - Molecular profiling services	‡	‡	‡
Cost of services - Pharma research and development services	‡	‡	‡
Gross profit	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023
Reportable Segment	812 100.00%	412 100.00%	306 100.00%
Revenue	812	412	306

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023
Reportable Segment	‡	‡	‡
Corporate and other	‡	‡	‡
Operating income	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023
United States	801 98.69%	402 97.47%	293 95.84%
International	11 1.31%	10 2.53%	13 4.16%
Revenue	812	412	306

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Caris Assure for therapy selection volume	Q2 FY2026	10.7K	7.1K	+49.73%
MI Profile for therapy selection volume	Q2 FY2026	48.3K	42.9K	+12.62%
Total clinical case volume	Q3 FY2026	61.5K	50.8K	+21.15%
Total matched profiles	Q3 FY2026	845.0K	660.0K	+28.03%
Total profiles	Q3 FY2026	1.2M	959.0K	+25.13%
Whole Exome profiles	Q3 FY2026	796.0K	577.0K	+37.95%
Whole Transcriptome profiles	Q3 FY2026	849.0K	628.0K	+35.19%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025
Caris Assure for therapy selection volume	‡	‡	‡	‡	‡	‡
MI Profile for therapy selection volume	‡	‡	‡	‡	‡	‡
Total clinical case volume	‡	‡	‡	‡	‡	‡
Total matched profiles	‡	‡	‡	‡	‡	‡
Total profiles	‡	‡	‡	‡	‡	‡
Whole Exome profiles	‡	‡	‡	‡	‡	‡
Whole Transcriptome profiles	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.